When there is a compelling need, in other subjects, to minimize the risk of hypoglycemia, DPP-4 inhibitors, thiazolidinediones, SGLT2 inhibitors, or GLP-1 receptor agonists may be added, except when cost is a major issue, in case thiazolidinediones or sulfonylureas could be given. This evidence concerns the gene DPP4 and Hypoglycemia.